$30M or more in 1Q20 product revenue (Daxi plus fillers) would be a good launch, IMO, bearing in mind that the first and third calendar quarters are slow periods for medical aesthetics.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.